named the new CEO of Lundbeck. In September 2019 Lundbeck announced it would acquire Alder BioPharmaceuticals $18 per share, valuing Alder at almost $2 billion. Key products Lundbeck markets a number of different pharmaceuticals for the treatment of psychiatric and neurological disorders. The most recently launched compounds include: Rexulti (depression and schizophrenia), Brintellix (depression) and Abilify Maintena (schizophrenia and bipolar 1). Lundbeck manufactures drugs such as: Products under development Brexpiprazole for Alzheimer's disease, bipolar disease and PTSD Foliglurax for Parkinson's disease Lu AF35700 for schizophrenia Controversy Lundbeck formerly held the only license to manufacture pentobarbital (Nembutal) in the United States. The drug is commonly used for execution by lethal injection in the United States (either as part of a three drug cocktail or by itself). After coming under criticism for not adding an ‘end user’ agreement to prevent importers from selling Nembutal to American prisons for use in executions, Lundbeck announced that it would not sell Nembutal to prisons in U.S. states that carry out executions. By introducing a new distribution system, Nembutal will be supplied exclusively through a specialty pharmacy drop ship program that will deny distribution of the product to prisons in U.S. states currently active in carrying out the death penalty by lethal injection. In December 2011 Lundbeck divested a portfolio of products including Nembutal to US pharmaceutical company Akorn Inc. As part of the agreement, Akorn committed to continue with Lundbeck's restricted distribution program for Nembutal, which was implemented to restrict the use of the product in the US. Since 2012, US prisons have reported a serious shortage of Nembutal. 2013 fine On June 19, 2013, the European Commission imposed a fine of €93.8 million on Lundbeck and fined several producers of generic pharmaceuticals a total of €52.2 million after Lundbeck made agreements in 2002 with the other companies to delay less expensive generics of Lundbeck's citalopram from entering the market. In return for the ability to maintain a monopoly on the drug's manufacture, Lundbeck offered payments and other kickbacks. See also Tarenflurbil, which the company had arranged for EU distribution rights on prior to termination of its development by Myriad. References External links The Lundbeck Institute Pharmaceutical companies of Denmark Life science companies based in Copenhagen Danish companies established in 1915 Valby Pharmaceutical companies established in 1915 Danish brands Multinational companies headquartered in Denmark Companies based in Copenhagen Municipality